{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:15:32Z","timestamp":1779282932349,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bulcan.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:27:05Z","timestamp":1758328025000},"page":"S58-S68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Choix du traitement pr\u00e9c\u00e9dant la r\u00e9injection des cellules CAR-T autologues en traitement des leuc\u00e9mies aigu\u00ebs lymphoblastiques de ph\u00e9notype B des patients de 0\u00a0\u00e0 25\u00a0ans (SFGM-TC)"],"prefix":"10.1016","volume":"113","author":[{"given":"C\u00e9cile","family":"Pochon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Rabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-5973","authenticated-orcid":false,"given":"Marie-Emilie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bulcan.2025.07.016_bib0270","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2025.07.016_bib0275","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2025.07.016_bib0280","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bulcan.2025.07.016_bib0285","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bulcan.2025.07.016_bib0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-024-01038-2","article-title":"Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r\/r ALL through a national access scheme","volume":"14","author":"Oporto Espuelas","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.bulcan.2025.07.016_bib0295","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19\u00a0CART-T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.07.016","article-title":"Clinical variables associated with improved outcomes for children and young adults treated with CART-T Cells for B-ALL: a decade of CAR-Translation","author":"Myers","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2025.07.016_bib0305","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CART-T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bulcan.2025.07.016_bib0310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CART-T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0315","article-title":"Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic B-lineage leukaemia in children and young adults","volume":"109","author":"Feuchtinger","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0320","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1182\/blood-2023-175045","article-title":"Low disease burden pre-CAR-T cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through intensification of the bridging therapy","volume":"142","author":"Lecornec","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2025.07.016_bib0325","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19-specific CART-T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11S","key":"10.1016\/j.bulcan.2025.07.016_bib0330","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0335","series-title":"Low disease burden pre-CAR-T cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through Intensification of the bridging therapy. In: ASH; 2023","author":"Lecornec","year":"2024"},{"issue":"11","key":"10.1016\/j.bulcan.2025.07.016_bib0340","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41375-021-01196-3","article-title":"Impact of bridging chemotherapy on clinical outcome of CD19\u00a0CART-T therapy in adult acute lymphoblastic leukemia","volume":"35","author":"Perica","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bulcan.2025.07.016_bib0345","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2025.07.016_bib0350","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2025.07.016_bib0355","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jtct.2023.08.030","article-title":"INSPIRED Symposium Part 2: prevention and management of relapse following chimeric antigen receptor T cell therapy for B cell acute lymphoblastic leukemia","volume":"29","author":"Lamble","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0360","article-title":"Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel","author":"Ravich","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"10.1016\/j.bulcan.2025.07.016_bib0365","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19\u00a0CART-T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0370","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2018-99-115593","article-title":"High vs. low-intensity bridging chemotherapy in children with acute lymphoblastic leukemia awaiting chimeric antigen receptor t-cell therapy: a population-based study from Ontario, Canada","volume":"132","author":"Gupta","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bulcan.2025.07.016_bib0375","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2025.07.016_bib0380","doi-asserted-by":"crossref","first-page":"e4749","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8\u00a0T cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.016_bib0385","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19\u00a0CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.bulcan.2025.07.016_bib0390","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19\u00a0CART-T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bulcan.2025.07.016_bib0395","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CART-T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.bulcan.2025.07.016_bib0400","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CART-T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.bulcan.2025.07.016_bib0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-139260","article-title":"Pre-CAR blinatumomab is associated with increased post-CD19\u00a0CAR relapse and decreased event free survival","volume":"136","author":"Taraseviciute","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2025.07.016_bib0410","doi-asserted-by":"crossref","first-page":"e007118","DOI":"10.1136\/jitc-2023-007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2025.07.016_bib0415","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","article-title":"Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"39","author":"Shah","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0420","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0425","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood-2021-148820","article-title":"Outcomes of children and young adults with acute lymphoblastic leukaemia administered inotuzumab pre CAR-T therapy","volume":"138","author":"Mullanfiroze","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2025.07.016_bib0430","doi-asserted-by":"crossref","first-page":"311.e1","DOI":"10.1016\/j.jtct.2023.02.012","article-title":"The choice of either conventional chemotherapy or inotuzumab ozogamicin as bridging regimen does not appear to impact clinical response to CD19-Directed CAR-T therapy in pediatric B-ALL","volume":"29","author":"Rubinstein","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.bulcan.2025.07.016_bib0435","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bulcan.2025.07.016_bib0440","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CART-T cell therapy","volume":"139","author":"Barz Leahy","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2025.07.016_bib0445","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2\u00a0study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.016_bib0450","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/leu.2012.324","article-title":"Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia","volume":"27","author":"Ottmann","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.bulcan.2025.07.016_bib0455","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2\u00a0trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.016_bib0460","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2025.07.016_bib0465","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"499","key":"10.1016\/j.bulcan.2025.07.016_bib0470","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CART-T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.bulcan.2025.07.016_bib0475","doi-asserted-by":"crossref","first-page":"e002582","DOI":"10.1136\/jitc-2021-002582","article-title":"Src\/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies","volume":"9","author":"Leclercq","year":"2011","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2025.07.016_bib0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1100105","article-title":"Case report: ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed\/refractory Philadelphia-like acute lymphoblastic leukemia","volume":"12","author":"Giglio","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2025.07.016_bib0485","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/s41375-023-02042-4","article-title":"Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"37","author":"Stackelberg","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bulcan.2025.07.016_bib0490","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ejh.14087","article-title":"Case report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation","volume":"112","author":"Canale","year":"2024","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.bulcan.2025.07.016_bib0495","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.07.016_bib0500","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real world CAR consortium report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.016_bib0505","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19\u00a0CART-T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bulcan.2025.07.016_bib0510","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2025.07.016_bib0515","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CART-T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.016_bib0520","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2019.10.016","article-title":"Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells","volume":"20","author":"Chen","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.bulcan.2025.07.016_bib0525","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.bbmt.2020.07.036","article-title":"Chimeric antigen receptor T cell therapy in patients with multiply relapsed or refractory extramedullary leukemia","volume":"26","author":"Rubinstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.bulcan.2025.07.016_bib0265","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:03:34Z","timestamp":1779282214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125003893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0007455125003893"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.07.016","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choix du traitement pr\u00e9c\u00e9dant la r\u00e9injection des cellules CAR-T autologues en traitement des leuc\u00e9mies aigu\u00ebs lymphoblastiques de ph\u00e9notype B des patients de 0\u00a0\u00e0 25\u00a0ans (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}